Broad Clinical Labs

Name

Broad Clinical Labs

Legal name

Broad Clinical Laboratories

Website

https://broadclinicallabs.org

Company type

Private

Founded year

2013

Operating status

Operating

Ownership category

akta.pro rank

Product category

Genomic Sequencing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Genomic sequencing services
• Clinical laboratory services
• Multi-omics analysis
• Whole genome sequencing
• Transcriptomics services

Headquarters

HQ city

Burlington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Clinical Genomic Sequencing Services: Fee-for-service model providing clinical-grade whole genome sequencing, whole exome sequencing, and blended genome-exome sequencing services to healthcare organizations, research institutions, and clinical trial sponsors. Services include sample processing, sequencing, analysis, and optional clinical interpretation and reporting.
2. Research Genomic Sequencing Services: Transactional pricing for research-grade sequencing services including whole genome sequencing, RNA sequencing, single cell sequencing, and microbial sequencing. Services priced per sample with various coverage and platform options.
3. Contract Assay Development Services: Custom assay development and validation services for clinical trials and therapeutic development, providing tailored solutions from planning through execution and ongoing support.
4. Walk-Up/Customer-Prepared Library Sequencing: Sequencing services for customer-prepared libraries including Illumina, PacBio, and Ultima platforms, priced per lane or flowcell with rapid turnaround options.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Broad Clinical Labs (BCL) operates a CLIA-certified, CAP-accredited genomic and multi-omic services laboratory that delivers clinical-grade and research-grade sequencing, including whole genome, whole exome, blended genome-exome, RNA, single cell, microbial, and proteomic assays. Services span sample processing, sequencing on Illumina NovaSeq X Plus, PacBio Revio, and Ultima platforms, DRAGEN-powered bioinformatics analysis, and optional clinical interpretation by board-certified geneticists. Offerings serve healthcare systems, research institutions, pharmaceutical and biotech companies, and government agencies across more than 50 countries.

Product overview

Broad Clinical Labs provides a comprehensive suite of clinical and research genomic sequencing services powered by multi-omics technology. The portfolio includes three clinical services (Clinical Whole Genome Sequencing with Interpretation, Clinical Whole Genome Sequencing, and Clinical Blended Genome-Exome Sequencing), three specialized services (Contract Assay Services, Clinical Trial Support, and Biomarker Discovery Platform), and ten research-grade sequencing services (Whole Genome Sequencing, Blended Genome-Exome Sequencing, Whole Exome Sequencing, Liquid Biopsy, Microbial WGS, RNA Sequencing, Single Cell Sequencing, Long-Read RNA Isoform Sequencing, Plasma Proteomic Profiling, and Walk-Up Sequencing). Services are performed in CLIA-certified and CAP-accredited facilities using Illumina NovaSeq X Plus, PacBio Revio, and other sequencing platforms, with bioinformatics powered by Illumina DRAGEN software.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Whole Genome Sequencing with Interpretation Comprehensive CLIA-certified PCR-free clinical whole genome sequencing on Illumina NovaSeq X Plus with expert interpretation by board-certified clinical laboratory geneticists, including variant evaluation, ACMG/AMP classification, clinical recommendations, and optional secondary findings for proband or family analysis.
• Clinical Whole Genome Sequencing CLIA-certified PCR-free clinical whole genome sequencing on Illumina NovaSeq X Plus with built-in pharmacogenomics data package, delivering CRAM, VCF, and PGx data files with approximately 28-day turnaround.
• Clinical Blended Genome-Exome Sequencing (cBGE) Combined low-coverage WGS (2-4x) and high-depth WES (85-100x) on NovaSeq X Plus that integrates monogenic and polygenic risk assessment in a single assay for clinical trials, population health programs, and cardiovascular risk testing, priced starting at $150 per sample.
• Contract Assay Services Customized laboratory test development, validation, and high-throughput processing for clinical studies and therapeutic development programs, providing end-to-end partnership from assay design through execution and ongoing support.
• Clinical Trial Support Regulatory-compliant genomic sequencing services for clinical trials including expert consultation, scalable clinical-grade sequencing, and advanced bioinformatics analysis and interpretation for pharmaceutical and biotech sponsors.
• Biomarker Discovery Platform Multi-omic biomarker discovery covering genomics, transcriptomics, and proteomics applications for drug discovery, clinical trials, precision medicine, and population health research.
• Research Human Whole Genome Sequencing Research-grade whole genome sequencing on Illumina NovaSeq X Plus (PCR-free and PCR-plus, 30x-80x) and PacBio Revio long-read platform (10x-40x HiFi), with DRAGEN bioinformatics analysis for structural variant, methylation, and haplotype phasing applications.
• Research Blended Genome-Exome Sequencing (BGE) Combined low-pass WGS (1-3x) and deeper WES (30-90x) in a single assay providing a cost-effective alternative to deep WGS or genotyping arrays for population genomics, GWAS studies, and rare variant discovery, starting at $120 per sample.
• Research Human Whole Exome Sequencing Research-grade germline and somatic whole exome sequencing using hybrid capture on Illumina NovaSeq 6000, delivering >98% coverage across RefSeq and GENCODE territories with over 1 million exomes processed to date.
• Cell-Free Tumor DNA Profiling via Liquid Biopsy Non-invasive tumor profiling using ultra-low-pass whole genome sequencing for tumor fraction estimation and targeted deep sequencing with UMI error correction, validated with 97-100% sensitivity for tumor fraction detection in cell-free DNA samples.
• Microbial Whole Genome Sequencing High-throughput microbial genome sequencing with tagmentation-based and non-tagmentation-based library construction supporting metagenomic, isolate, Plasmodium, and fungal applications with multiplexing capabilities.
• RNA Sequencing Comprehensive transcriptomics services including Total RNA, Stranded mRNA, SmartSeq2, and Transcriptome Capture, processing 25,000+ transcriptomes annually with capabilities for FFPE and low-input samples.
• Single Cell Sequencing High-precision single cell solutions including 10x Genomics Gene Expression (3' or 5'), Single Cell Multiome (ATAC + Gene Expression), and SmartSeq2, supporting fresh frozen, PBMC, tumor tissue, and archived specimens for cellular analysis and drug discovery applications.
• Long-Read RNA Isoform Sequencing (MAS-Seq) Full-length RNA isoform sequencing using PacBio Kinnex MAS-seq technology, generating 30-50 million HiFi reads per array with assembly-free isoform identification and fusion detection.
• Plasma Proteomic Profiling High-throughput proteomics using Olink Explore HT platform profiling 5,400+ validated protein assays per sample, enabling biomarker discovery, pharmacokinetic analyses, and patient stratification.
• Sequencing of Customer-Prepared Libraries (Walk-Up Sequencing) Rapid sequencing service for pre-constructed libraries and library pools on Illumina NovaSeq X Plus, PacBio Revio, and Ultima Genomics UG 100 platforms with two-business-day turnaround and single-lane options, with walk-up drop-off available for Boston-area customers.

Quantifiable outcome

• Reduced diagnostic odyssey from multi-day to same-day turnaround with SBX technology (<4 hours vs. standard 2-5+ days)
• +7 more outcomes

Named customers15 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Partnerships

14 partnerships are on record, tiered minor and core.

• BioptimusminorStrategic or Co-development Partner · 25 March 2026Collaboration on STELA (Spatial Transcriptomics Enabled by Long-read Analysis) project - the world's largest clinically linked spatial biology atlas. BCL will profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing ~20x increase in scale over existing data.
• Boston Children's HospitalcoreStrategic or Co-development Partner · 15 October 2025Collaboration with Roche and BCL to achieve Guinness World Record for fastest DNA sequencing technique. The team applied SBX technology to NICU samples demonstrating same-day workflow from blood to report. Clinical application enables rapid genetic diagnosis for infants with suspected genetic disorders, potentially transforming NICU care paradigms.
• Roche Sequencing SolutionscoreTechnology or Integration · 23 May 2025Strategic collaboration to develop and pilot Roche's next-generation SBX (Sequencing By Expansion) technology. First project focuses on trio-based whole genome sequencing for critically ill newborns in NICUs. The collaboration aims to establish SBX as a routine offering for fast, scalable sequencing and explores applications in RNA sequencing including bulk and single-cell approaches. SBX achieved Guinness World Record for fastest DNA sequencing at <4 hours for whole genome.
• National Multi-Omics AcceleratorcoreStrategic or Co-development Partner · 9 April 2025BCL serves as the operational engine for the National Multi-Omics Accelerator, providing inclusive access to translational science and technology. The program focuses on bringing advanced omics capabilities to underserved populations and communities.
• IlluminacoreTechnology or Integration · 2 March 2025Collaboration to rapidly streamline and scale single-cell workflows toward the goal of a 5 billion single-cell atlas within three years. BCL utilizes Illumina's Single Cell Prep, NovaSeq X Plus platform, 25B flow cell, and DRAGEN analysis software workflow along with Perturb-seq, CRISPR screens, and other platforms to help researchers process and analyze single-cell samples at unprecedented volumes.
• Everygene / Heartgene SciencescoreStrategic or Co-development PartnerEverygene's nationwide cardiomyopathy testing program leverages BCL's clinical BGE sequencing services to deliver free genetic testing to patients across the United States. Heartgene, co-founded by BCL webinar speaker Megan Sutton, provides genetic testing and counseling for inherited cardiomyopathies using BCL's cBGE platform, addressing the gap where fewer than 2% of cardiomyopathy patients receive genetic evaluation.
• Mass General Brigham - Laboratory for Molecular MedicinecoreStrategic or Co-development PartnerPartnership for expert variant interpretation in clinical genetic testing programs. The Laboratory for Molecular Medicine at Mass General Brigham provides clinical-grade variant interpretation for BCL's cardiovascular genetic testing and other clinical programs. Also collaborated on launching genetic testing for inherited cardiovascular risk across eight conditions.
• Boston Children's Hospital and Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerPartnership to develop BrightSeq initiative transforming how rare pediatric cancers are detected and monitored. Leverages BCL's precision genomics, liquid biopsy technologies, and scalable clinical operations to provide critical diagnostic insights while advancing pediatric cancer research globally.
• Department of Veterans Affairs (VA) - ProGRESS StudycoreStrategic or Co-development PartnerVA's groundbreaking ProGRESS clinical trial leverages BCL's clinical BGE sequencing services to generate both monogenic and polygenic risk scores for veterans, creating personalized prostate cancer screening protocols. First-of-its-kind trial demonstrating integrated genomic data can transform cancer screening.
• Southern Research - Catalyst ProgramminorStrategic or Co-development PartnerSouthern Research's Catalyst program uses BCL's clinical BGE sequencing services to bring free genetic testing to underserved Alabama communities - a state ranking 49th in life expectancy. Program provides comprehensive disease risk assessment and pharmacogenomics to patients and primary care providers.
• TakedaminorStrategic or Co-development PartnerTakeda partnered with BCL to analyze patient samples from their Phase III multiple myeloma trial of Ninlaro. Through collaborative design of a targeted panel interrogating 754 genes, BCL's RNA sequencing and DNA mutational analysis helped unlock insights into multiple myeloma biology and treatment resistance mechanisms.
• Dana-Farber Cancer InstituteminorStrategic or Co-development PartnerBCL provided sequencing expertise for Dana-Farber's phase 1 trial of NeoVaxMI, an updated personalized cancer vaccine for melanoma published in Cell. BCL's sequencing supported research demonstrating improved vaccine-specific immune responses. Also supported whole exome sequencing analysis of 1,459 sickle cell disease patients.
• Delve BiominorStrategic or Co-development PartnerAccelerated by BCL's high-throughput capabilities and expertise, Delve Bio scaled their metagenomic NGS platform nationwide, providing rapid answers for patients with complex neurological infections. Enables clinicians to achieve definitive diagnoses for challenging cases of meningitis and encephalitis in just two days.
• 10x GenomicscoreTechnology or IntegrationTechnology partner for single cell sequencing services. BCL utilizes 10x Genomics platforms including Single Cell Gene Expression (3' and 5'), Single Cell Multiome (ATAC + Gene Expression) for cellular analysis and drug discovery applications.

Scale indicators21 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Helix: Helix operates a CLIA-certified, CAP-accredited clinical genomics lab offering exome + Sanger confirmatory testing and population genomics programs. Direct peer in clinical genomic lab services and population health screening.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors and hematologic malignancies. Peer in clinical cancer genomics with overlapping pharma/biotech companion diagnostic and clinical trial customers; also a sister Roche entity to BCL's SBX collaborator.
• GeneDx: GeneDx is a clinical genomics lab specializing in rare disease, pediatric, and hereditary cancer testing. Direct peer to BCL in clinical WGS/WES interpretation services; both compete for hospital and health system clinical sequencing contracts.
• Tempus: Tempus is a clinical genomics and AI-driven precision medicine company offering NGS, liquid biopsy, and multi-omic profiling. Comparable to BCL's clinical trial support, biomarker discovery, and clinical oncology sequencing services.
• Caris Life Sciences: Caris offers molecular profiling services (MI Profile, MI Cancer Seek) for oncology using WES/WTS and AI-driven analytics. Comparable to BCL's liquid biopsy and tumor profiling services and competes in pharma clinical trial molecular profiling.
• Color Health: Color Health provides population-scale clinical genetic testing including hereditary cancer and pharmacogenomics. Comparable to BCL's cBGE-based population genomics programs (VA ProGRESS, Catalyst) and competes for the same enterprise health system and employer contracts.
• Natera: Natera provides cell-free DNA and molecular testing across oncology, women's health, and organ health. Comparable to BCL's liquid biopsy and clinical sequencing services, particularly in cell-free tumor DNA and rare disease diagnostics.
• Exact Sciences (Genomic Health): Exact Sciences' Genomic Health business provides Oncotype DX and other genomic oncology tests. Peer in clinical cancer genomics with comparable pharma/biotech partnerships and clinical interpretation offerings.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is one of the largest clinical laboratory networks in the U.S., offering an expanding menu of genomic and molecular tests. Broad incumbent that competes with BCL on hospital/health system clinical sequencing contracts but with much larger test menu and commercial reach.
• Laboratory Corporation of America (Labcorp): Labcorp is a major clinical laboratory network with substantial genomic testing capabilities (including via its Invitae acquisition). Broad incumbent competing with BCL in clinical sequencing, women's health, and oncology testing at enterprise scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/broad-clinical-labs

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Broad Clinical Labs